Pharma companies don’t have to comply. Large pharmaceutical companies are notoriously risk averse when it comes to expanding access to medications that are still in the testing phase. Many refuse to grant access to investigational drugs outside of clinical trials, and efforts to lobby them to release the medication as part of compassionate use are often rebuffed

Quick Read

The new law has a catchy name, but it will only make it more difficult to know if medication is effective or safe

Quick Read

Our Gail Javitt writes, “The reality is that Right to Try is unlikely meaningfully to increase the number of terminally ill patients who can access investigational therapies or improve the outcomes for such patients. Those that claim otherwise, and who cast FDA as the primary obstacle between dying patients and lifesaving medicines, are peddling their own form of ‘snake-oil'”

Quick Read

Be the first to like. Like Unlike

Quick Read

Be the first to like. Like Unlike

Quick Read

The Food and Drug Administration’s crusade against irresponsible stem cell clinics is heating up. On Wednesday, the agency announced it was seeking permanent injunctions against two of the most prominent clinics in the US. The injunctions, if successful, would bar the clinics and specific doctors there from performing unapproved stem cell therapies

Quick Read

What one city did to fight high drug prices reveals a drug supply chain in which just about every link can benefit when prices go up

Quick Read

Stem cell clinics multiply, with heartbreaking results for some patients

Quick Read